Screening and Treatment of Mid-trimester Short Cervix in Asymptomatic Pregnanacies

I. Background
- A short cervix identified in the midtrimester of pregnancy is a strong predictor of preterm birth in all populations studied [1]
  - Effacement begins at the internal cervix os and progresses caudally, thus precedes dilatation
- Despite the strong association between short cervical length and preterm birth, most women with asymptomatic cervical shortening deliver at >35 weeks [2]

II. Goals
A. The purposes of cervical length screening are:
  1. Identify populations of patients in which the following interventions may be beneficial:
     - Vaginal progesterone
     - Cerclage
     - Antenatal corticosteroids
  2. Avoid unnecessary interventions and subsequent screening tests in women at low risk of preterm birth. Only extremely short cervical lengths in asymptomatic patients in the midtrimester are associated with a significant risk of impending preterm birth within 2-4 weeks.
    - Women with no measurable cervical length in the midtrimester have a median time from diagnosis to delivery of 3 weeks, 65% do not deliver within 2 weeks, with only 36% risk of delivery by 32 weeks of gestation.[3]
B. Protocols that incorporate universal cervical length screening have demonstrated a reduction in frequency of preterm birth. [4, 5]
C. Universal transvaginal (TV) CL screening in all pregnant women is not mandated by ACOG, however, it is a reasonable evidence-based practice pattern. [6, 7] It is the preferred approach at UC. If TV CL is declined, the cervix should be visualized by abdominal approach.

III. Midtrimester (16-24 weeks) with Short Cervix
A. Treatments with proven benefit for asymptomatic cervical shortening:
  1. Vaginal progesterone
    - Several vaginal progesterone preparations have reported efficacy for preterm birth prevention with short cervix. [4, 5, 8, 9] A meta-analysis of trials of vaginal progesterone has demonstrated efficacy in all patients studied with cervical length ≤25 mm. [10]
    - The most commonly used preparation is Prometrium® 200mg capsule PV qHS
    - Treatment can be discontinued at 37 wks or earlier if development of PROM.
      - 17-OHPC does not reduce the risk of PTB with incidentally noted short cervix and is not recommended as an alternative to vaginal progesterone in women with short cervix. [11]
  2. Cerclage
    - Women with a prior spontaneous preterm birth <34 weeks AND a short cervical length < 25 mm at <23 weeks, benefit from cerclage, OR 0.60 (0.37, 0.98), data from RCT. [12-15] When stratified, benefit is limited to those with shortest CL <15 mm, OR 0.23 (CI 0.08, 0.66), versus non-significant reduction for CL 15-24 mm, OR 0.84 (0.49, 1.4).
• Women with no prior spontaneous preterm birth and very short cervix <10 mm have shown to benefit from cerclage (RR 0.68, CI 0.47, 0.98), data from subgroup analysis of a meta-analysis (small n=126). [16]. Option of cerclage will be discussed with patients who meet these criteria.

• Women with asymptomatic cervical dilation may benefit from exam indicated cerclage, mean pregnancy prolongation 34 days (CI 18-50 days), data from large meta-analysis [6, 17]

  • Cervical shortening often precedes asymptomatic cervical dilation. Up to one third of women with CL ≤11 mm on TVUS also have cervical dilation of ≥1cm. [18] Therefore, when asymptomatic cervical shortening ≤11 mm is noted on ultrasound <23 weeks, digital cervical exam is advised to assess whether physical exam indicated cerclage may be indicated.

3. Antenatal corticosteroids
   Improve neonatal outcomes when administered in pregnancies at risk of preterm birth. Optimum benefit is when administered in pregnancies likely to deliver within 2 weeks, i.e. in women with extremely short cervical lengths (less than 5 mm), see Antenatal Corticosteroid protocol

4. Pessary
   Current data do not support efficacy of pessary to prevent preterm birth in singleton or twin pregnancies with short cervix. Therefore, pessary is not recommended in the management of short cervix.[6]

B. Treatments with NO proven benefit for asymptomatic cervical shortening
   1. Bed rest and pelvic rest
      have not been proven to improve perinatal outcomes in women with mid-trimester cervical shortening and may in fact be harmful.[19] Based on available evidence, we do not encourage activity limitations in women with asymptomatic cervical shortening in an effort to decrease preterm birth risk. Recommendations on activity limitations will be individualized after consultation with her primary OB care provider.

   2. Prophylactic tocolytic agents in patients with no evidence of preterm contractions (i.e. calcium channel blockers)

   3. Prophylactic antibiotics in patients with no evidence of infection

IV. Cervical length screening in selected populations

A. History suspicious for cervical insufficiency [20]
   1. Women with history consistent with cervical insufficiency: offer history-indicated cerclage placement at 12-14 weeks (i.e. women with one or more prior second-trimester loss related to painless cervical dilation or those with a history of successful cerclage in prior pregnancy).
      This prior history does not exclude women with current twin pregnancy.

   2. Women with equivocal history, unclear whether there is cervical insufficiency: Offer serial CL screening and cerclage if short cervix identified. Initiate TV ultrasound cervical lengths at **14 weeks**
      If CL ≥30 mm, repeat every 2 weeks until 22 6/7 weeks
      If CL 25-29 mm, repeat every 1 week until 22 6/7 weeks
      If CL ≤25 mm, offer cerclage placement
**B. History of spontaneous preterm birth in prior pregnancy** at 17 to <34 weeks (see figure)[15]

1. Initiate TV ultrasound cervical lengths at **16 weeks**
   - If CL ≥30 mm, repeat every 2 weeks until 22 6/7 weeks
   - If CL 25-29 mm, repeat every 1 week until 22 6/7 weeks
   - If CL <25 mm, offer cerclage placement
2. No further scheduled CL screening after 22 6/7 weeks
3. Special scenarios:
   - Both vaginal progesterone and cerclage have shown benefit with short cervix in this population, however they have not been compared to each other for superiority. Both should be discussed as treatment options. It is not known if placing cerclage in women already taking vaginal progesterone is additionally beneficial, but may be offered. [6]
   - Women with **history of preterm labor but delivered at term** do not fit in this category and should be treated as Low Risk.

**C. Multifetal gestation**

1. Single TV US cervical length at **18-24 weeks**, at anatomic survey
   - If ≤25 mm, vaginal progesterone
   - If >25 mm, routine care
   a. For short cervix, consider vaginal progesterone
      - There are conflicting results from trials regarding efficacy of vaginal progesterone to prevent preterm birth in twin gestations with short cervix ≤25 mm, some showing benefit and others no benefit. [8, 21] However, vaginal progesterone is reasonable intervention considering its potential benefit and no known risk [4]
   b. There is insufficient data to recommend for or against cerclage for short cervix in multifetal gestation. [22, 23]
   c. Asymptomatic cervical dilation in twin pregnancies- exam indicated cerclage- may be offered based on RCT data demonstrating benefit in this population. [24]

**D. Low Risk singletons** (nulliparous or multiparous with prior term birth – includes pregnancies with other risk factors such as history of LEEP or uterine malformation), figure 1

1. Recommended screening is:
   - Single TVUS cervical length at **18-24 weeks**, at anatomic survey
     - If ≤25 mm, offer vaginal progesterone[10]
     - If >25 mm, routine care
   - Women with very short cervix <10 mm may also benefit from cerclage and it should be discussed with the patient.[16]

**V. Counseling**

A. Provide patient information regarding estimated likelihood of PTB based on the specific CL at gestational age when assessed, see appendix. [2, 17, 25, 26]

B. Patients with normal cervical length > 25 mm, but otherwise at high risk of preterm birth (twins, prior preterm birth, etc) may be reassured regarding low risk of PTB by providing individualized risk assessment, see appendix.
VI. Special Situations
   A. Cerclage during periviable period
      • Cerclage is typically placed <23 weeks. Some patients may be candidates for cerclage between 23 0/7 – 23 6/7 weeks based on individualized counseling on risks/ benefits by MFM.
      • In most circumstances, women receiving ultrasound indicated cerclage at ≥22 0/7 weeks do not warrant perioperative ANCS.
      • Women receiving exam indicated cerclage at ≥22 0/7 weeks may be candidates for ANCS based on individualized counseling on risks/ benefits
   B. TTTS
      • Some women with TTTS and short cervix may be candidates for ultrasound indicated cerclage up to 23 6/7 weeks based on individualized counseling on risks/ benefits by fetal care team.
   C. Screening with TV CL after cerclage
      • Role of CL screening after intervention provided is uncertain and generally not advised.
      • For ultrasound and exam indicated cerclage, it is reasonable to repeat a cervical length one week following cerclage placement. There is no benefit to serial cervical length screening thereafter.
      • CL screening after cerclage may assist to identify patients at high risk of impending preterm birth (i.e. funneling to the stitch or residual CL ≤5 mm). Therefore, in special circumstances, further cervical length screening after cerclage may be individualized.
   D. Inpatient admission and antenatal corticosteroid administration
      • Extremely short cervical lengths, ≤5 mm, prior to 28 weeks may be associated with a significant enough likelihood of preterm birth within 2 weeks to warrant inpatient management and steroid administration (mean latency with CL = zero is 3 weeks, 36% risk of delivery within 2 weeks[3])
      • Women with other concomitant risk factors may warrant inpatient management at CL >5 mm. Recommend individualized treatment with MFM consultation.
   E. Preterm contractions
      • Women with preterm contractions and short cervix are at especially high risk of preterm birth and should be managed by the Preterm Labor Protocol and not based on recommendations in this protocol, which is focused on the short cervix in asymptomatic women.

VII. Measuring the Cervix
   • Cervical length should only be determined from images in which the lower most edge of the empty maternal bladder and the internal os and external os are visible and when the anterior and posterior lips of the cervix are of approximately equal thickness. At least 3 measurements should be captured and the single shortest measurement should be reported. Reporting additional findings such as funneling, change in length over serial measures, or change in length with fundal pressure do not add to the predictive value of reporting the single shortest cervical length measurement alone. [6, 27, 28]
### Short Cervix Protocol
Revised May 2022

**Figure: Cervical Length Screening:**

- **Universal Cervical length screening** *(Singleton gestation)*

  - **No prior preterm birth**
    - **Single TVU CL at 18-22 6/7 weeks**
      - **CL ≤25 mm**
        - Vaginal Progesterone
          - **CL <10 mm, Consider cerclage**
      - **CL > 25 mm**
        - Routine care

  - **Prior spontaneous preterm birth <37 weeks**
    - **Offer progesterone**
      - **If prior sPTB <34 weeks Serial TVU CL at 16-22 6/7 weeks**
        - **CL ≤ 25 mm**
          - Offer cerclage If receiving progesterone, continue
        - **CL > 25 mm**
          - If receiving progesterone, continue
References:

Appendices

Singletons:

Estimate the risk of preterm birth by cervical length:

Twins:

Figure 2 Predicted probability of delivery of twin pregnancies before 35 weeks’ gestation based on cervical length and gestational age (GA) at time of measurement. ◆, GA 16 weeks; ▲, GA 20 weeks; ◇, GA 24 weeks; ▣, GA 28 weeks.